摘要 |
This invention is directed to methods of using compounds having the structure: and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3 </SUP>and R<SUP>4 </SUP>is independently selected from hydrogen, R<SUP>5</SUP>, R<SUP>6</SUP>, and R<SUP>7</SUP>; R<SUP>5 </SUP>is selected from alkyl, heteroalkyl, aryl and heteroaryl; R<SUP>6 </SUP>is selected from (R<SUP>5</SUP>)<SUB>n</SUB>-alkylene, (R<SUP>5</SUP>)<SUB>n</SUB>-heteroalkylene, (R<SUP>5</SUP>)<SUB>n</SUB>-arylene and (R<SUP>5</SUP>)<SUB>n</SUB>-heteroarylene; R<SUP>7 </SUP>is selected from (R<SUP>6</SUP>)<SUB>n</SUB>-alkylene, (R<SUP>6</SUP>)<SUB>n</SUB>-heteroalkylene, (R<SUP>6</SUP>)<SUB>n</SUB>-arylene, and (R<SUP>6</SUP>)<SUB>n</SUB>-heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R<SUP>1 </SUP>and R<SUP>2 </SUP>may together form a heterocyclic structure including the nitrogen to which they are both attached, and R<SUP>3 </SUP>and R<SUP>4 </SUP>may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L<SUP>1 </SUP>and L<SUP>2 </SUP>is independently selected from -A1-A2-A3- where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene. These compounds are useful in treating hyperproliferative disorders and inducing apoptosis.
|